Special Issue

Personalized Medicine for Liver Disease: From Molecular Mechanisms to Potential Targeted Therapies

Message from the Guest Editor

The liver is a vital organ responsible for a myriad of biologic functions

A variety of genetic and/or environmental factors, e.g., viruses, diet, alcohol, and microbiome, among others, can result in impaired liver function, steatosis, fatty liver disease, diabetes, cirrhosis, and cancer. Often, these are the result of altered transcriptional regulation of key liver genes and/or gene regulatory networks. Such transcriptional reprogramming has resulted in the discovery of novel biomarkers and therapeutic targets for precision medicine treatments of liver diseases. The aim of this special issue is to provide an overview of exciting new cutting-edge research in the area of molecular regulation of liver diseases that may garner novel therapeutic targets for precision medicine. We invite the submission of original research and review articles on molecular regulation of liver diseases, including studies on molecular and cellular mechanisms, molecular functional studies, personalized and precision medicine, biomarker discovery and validation, gene and molecular therapies, and liver disease models.

Guest Editor

Dr. Aaron W. Bell

Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15261, USA

Deadline for manuscript submissions

closed (25 September 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/59595

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

